Phase 4 N=355 Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia
Schizophrenia · Psychotic Disorders
Primary: Time to Relapse — 131; 113 days — p=0.684
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=42 Visual Outcomes of Subjects Bilaterally Implanted With ReSTOR Aspheric +4 vs. Tecnis or Acri.LISA
Cataract
Primary: Uncorrected Visual Acuity (UCVA) at Distance, Near and Intermediate — 0.02; 0.01; 0.20; 0.20 logMAR
Phase 4 N=35 Long-term Safety of Minocycline in Patients With Gum Disease
Periodontitis
Primary: Change in Percent of Minocycline-Resistant Bacteria Using Bacterial Culture — 13.15; 0.81; 37.65; -2.25 Percentage Change
Phase 4 N=52 Contralateral ReSTOR / Monofocal or Phakic Eye
Cataracts
Primary: Visual Acuity — -0.04; -0.01; 0.14; 0.18 LogMar
Phase 4 N=50 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)
Allergic Conjunctivitis
Primary: Change in "Ocular Itching" Score (5-point Scale) in Subjective Symptom Questionnaire — 0.19; 0.11; 0.06; 0.08 Units on a scale
Phase 4 N=30 Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)
Angle-closure Glaucoma
Primary: Mean Intraocular Pressure (IOP) — 15.77; 18.35 millimeters mercury (mm Hg)
Phase 4 N=121 PleuraSeal Post Market Study (Europe)
Lung Disease · Pulmonary Lobectomy
Primary: Percentage of Subjects Remaining Air Leak Free From Time of Skin Closure to Hospital Discharge. — 41.9; 30.5 Percentage of participants — p=0.257
Phase 4 N=50 Study of Ocular Penetration of Topically Administered Fluoroquinolones
Cataract Extraction
Primary: Aqueous Humor Concentration of Study Drug — 1.6108; 0.0312 µg/ml — p=<0.0001
Phase 4 N=280 ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (IOL)
Cataract
Primary: Binocular Distance Corrected Near Visual Acuity at Best Distance (That Which Provides the Subject With the Best Vision) — 0.07; 0.09 logMAR
Phase 4 N=543 EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA
Cerebrovascular Accident
Primary: Telephone Modified Rankin Scale (Centralised, Blinded Assessment) — 58; 70; 75; 84 participants — p=0.683
Phase 4 N=46 A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension
Glaucoma · Ocular Hypertension
Primary: Intra Ocular Pressure (IOP) — 179.20; 191.89; 188.82; 196.26 mm Hg (millimeters mercury)*week
Phase 4 N=401 Mometasone Furoate on Sleep Disturbances in Subjects With Seasonal Allergic Rhinitis (Study P04608) (COMPLETED)
Seasonal Allergic Rhinitis
Primary: Mean Change of the AM-PRIOR-reflective (Participant's Status Over the Previous 12 Hours) Total Nasal Symptoms Severity Score (TNSS) Averaged Over the Last 7 Days of…
Phase 4 N=130 Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial
Seasonal Allergic Rhinitis
Primary: Mean Percent Change in Reflective Total Nasal Symptom Score (rTNSS) From Baseline — -45.37; -47.35 Percent change
Phase 4 N=293 Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant
Liver Transplantation
Primary: Change From Baseline in Glomerular Filtration Rate (GFR) at 12 Months Posttransplant — 1.2; 19.7 Percent change in GFR (mL/min) — p=0.0012
Phase 4 N=344 Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD
Pulmonary Disease, Chronic Obstructive
Primary: Post-dose TGV(FRC) (After 8 Weeks) — 4.99; 5.07 Litres — p=0.0482